Stay updated with breaking news from Alexion shares. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
12 december 2020 kl 13:59 Greater scientific presence in immunology by adding Alexion s innovative complement-technology platforms and strong pipeline Dedicated rare disease unit to be headquartered in Boston Geographical presence to be enhanced with broad coverageacross primary, speciality and highly specialised care Double-digit revenue growth through 2025; acquisition strengthens AstraZeneca s broad-based revenue and the company will further globalise Alexion s portfolio Enhanced operating margin and cash flow to enable rapid debt reduction with an ambition to increase the dividend The acquisition will be immediately core earnings-accretive andvalue-enhancing, and is aligned with stated capital-allocation priorities AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. ....
Press release content from Business Wire. The AP news staff was not involved in its creation. AstraZeneca to Acquire Alexion, Accelerating the Company’s Strategic and Financial Development December 12, 2020 GMT CAMBRIDGE, England & BOSTON (BUSINESS WIRE) Dec 12, 2020 AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca’s reference average ADR price of $54.14, this implies total consideration to Alexion shareholders of $39bn or $175 per share. ....